pharmaphorum May 28, 2024
Asahi Kasei has offered to buy Sweden’s Calliditas Therapeutics for SEK 11.8 billion ($1.1 billion) as part of a plan to expand internationally in healthcare.
The Japanese group’s tender offer is a premium of around 83% on Calliditas’ closing share price yesterday and has been recommended by the biotech’s board, which says a takeover would enhance its ability to develop and commercialise its products.
Calliditas specialises in developing drugs for rare diseases and has one product on the market – corticosteroid-based Tarpeyo (budesonide) for IgA nephropathy (IgAN), which is also sold as Nefecon in China and Kinpeygo in Europe – and a pipeline headed by dual NADPH oxidase (NOX4/1) inhibitor setanaxib.
The Swedish company is projecting sales of Tarpeyo will...
Today's Sponsors
Today's Sponsor